Clinical trials: Anticoagulant
Direct Oral Anticoagulant, Hemmorhage
Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly
This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.
- Conditions
- Direct Oral Anticoagulant, Hemmorhage, Elderly, Muscle Mass
- Trial name
- SARCORRHAGED (NCT07173075)
- Testing
- impedancemetry
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Clermont-Ferrand
Stable Angina, Unstable Angina
COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate the incidence of bleedings (COSTA-Bleed) and the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with the abluminal…
- Conditions
- Stable Angina, Unstable Angina, STEMI, NSTEMI
- Trial name
- COSTA (NCT02723981)
- Testing
- COMBO-Stent, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran, Any drug eluting stent oder bare metal sent
- Where
- 10 sites in Germany
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Atrial Fibrillation
Pleotropic Effect of New Oral Anticoagulants
Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel.
- Trial name
- NCT02544932
- Testing
- dabigatran, ribaroxaban, Warfarin
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Kyunghee University Medical Center
Thrombosis
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
- Trial name
- NCT01379300
- Testing
- dabigatran etexilate, rivaroxaban
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Non-valvular Atrial Fibrillation
Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program
This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up.
- Trial name
- MONACO (NCT02422602)
- Testing
- Xarelto, Experimental: Personalized information intervention
- Where
- France
- Volunteers
- 196 people
- Sponsor
- University Hospital, Montpellier
Hypercoagulable States
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
Retrospective, cohort study chart review in patients with hypercoagulable states.
- Trial name
- NCT04565977
- Testing
- Observational
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Methodist Health System
Atrial Fibrillation
This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain
This is an observational, multicenter and cross-sectional study in Non-valvular atrial fibrillation (NVAF) elderly patients currently on Non-vitamin K antagonist oral anticoagulant (NOAC) treatment for their stroke prevention.
- Trial name
- NCT03993119
- Testing
- Non-vitamin K antagonist oral anticoagulant
- Where
- 45 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism…
- Trial name
- NCT00788736
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 2,537 people
- Sponsor
- Ottawa Hospital Research Institute
Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient
Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System
The thrombin generation test is a global test for the study of coagulation that allows the fine study of the balance between procoagulant and anticoagulant factors.
- Conditions
- Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient, Patient With FV Leiden Mutation, Patient With Cirrhosis
- Trial name
- EVIGE (NCT05422157)
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Clermont-Ferrand
Venous Thromboembolism, Patient-Centered Care
Anticoagulation Medical Home
The primary study goal is to improve the quality of care transitions for patients with new episodes of venous thromboembolism (VTE).
- Trial name
- NCT02870296
- Testing
- Enhanced Assessment and Education
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Bleeding
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding.
- Trial name
- NCT06575517
- Sponsor
- AstraZeneca
Cerebral Hemorrhage
Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage
This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH).
- Trial name
- NCT00029315
- Testing
- Recombinant Tissue Plasminogen Activator (rt-PA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Cerebral Hemorrhage, Stroke
The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial
Continued uncertainty exists over benefits of early intensive blood pressure (BP) lowering in acute intracerebral hemorrhage (ICH), related to the non-significant primary outcomes, patient selection, and discordant results of…
- Conditions
- Cerebral Hemorrhage, Stroke, Hypertension, Diabetes
- Trial name
- INTERACT3 (NCT03209258)
- Testing
- Care bundle of active management, Usual care
- Where
- China
- Volunteers
- 7,067 people
- Sponsor
- The George Institute for Global Health, China
Atrial Fibrillation, Coronary Artery Disease
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months…
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Stable Angina, Stable Chronic Angina
- Trial name
- EPIC-CAD (NCT03718559)
- Testing
- Edoxaban Monotherapy, Edoxaban plus Single Antiplatelet Agent
- Where
- 18 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Gi-Byoung Nam
Venous Thromboembolism, Deep Vein Thrombosis
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
Lower limb trauma requiring immobilization is a very frequent condition that is associated with an increased risk of developing venous thromboembolism (VTE).
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism, Lower Limb Trauma
- Trial name
- RIVACAST (NCT06195540)
- Testing
- Rivaroxaban 10 MG, Low Heparin Molecular Weight
- Where
- 37 sites in France
- Volunteers
- 1,424 people
- Sponsor
- University Hospital, Angers
Long-term Oral Anticoagulant Therapy
Bemiparin Randomized Trial on Bridging Oral Anticoagulants in Invasive Procedures (BERTA Study)
Often it is necessary to temporarily discontinue OAT when surgical or other invasive procedures are required. However, there is no consensus on the optimal management in these situations, and heparin bridging therapy is the…
- Trial name
- BERTA (NCT00484822)
- Testing
- Bemiparina Sodica, Heparina Cálcica
- Where
- 31 sites in Spain
- Volunteers
- 206 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Platelet Thrombus
Anti-Inflammatory and Anti-Coagulant Effects of Salmon Polar Lipids
Inflammation is a normal immune response to tissue healing. However, uncontrolled and unresolved inflammation can initiate and further induce several chronic manifestations that contribute to chronic disorders such as…
- Trial name
- NCT03866265
- Testing
- Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)
- Where
- Ireland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Limerick
Atrial Fibrillation, Anticoagulants and Bleeding Disorders
Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
The aim of this study is to compare the safety and efficacy of edoxaban and warfarin for prevention of stroke during a 6-month follow up after total thoracoscopic ablation.
- Trial name
- NCT04121767
- Testing
- Edoxaban, Warfarin
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Simulation Training, Anticoagulant Drugs
E-learning to Improve Oral Anticoagulant Use in Hospitalized Older People With AF
Atrial Fibrillation (AF) is the most common cardiac arrhythmia and the main cause of cardioembolic stroke. Oral Anticoagulation (OAC) has been shown to significantly prevent AF-related thromboembolism, however, despite convincing…
- Conditions
- Simulation Training, Anticoagulant Drugs, Elderly, Atrial Fibrillation
- Trial name
- SIM-AF (NCT03188211)
- Testing
- E-learning educational program, Control
- Where
- 20 sites in Italy
- Volunteers
- 247 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Anticoagulant Therapy
A Clinical Study of Lyophilized Plasma in Patients on Warfarin
This is a multi center, phase 2 randomized controlled study to determine the effect of lyophilized plasma in patients on warfarin therapy.
- Trial name
- NCT01541098
- Testing
- Lyophilized Plasma, Licensed Plasma
- Sponsor
- HemCon Medical Technologies, Inc